Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072148 · ClinicalTrials.gov registry record · NA
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
A NA study of Human Papilloma Virus and Oropharyngeal Squamous Cell Carcinoma, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 2
- Study locations
NCT02072148 is a NA study of Human Papilloma Virus and Oropharyngeal Squamous Cell Carcinoma that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 112 participants, below the 620-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02072148, a NA study of Human Papilloma Virus and Oropharyngeal Squamous Cell Carcinoma, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 2
- Study locations
Study Summary
In general, patients with Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma (HPVOPC) are curable, young and will live for prolonged periods. They are at high risk for long-term toxicity and mortality from therapy. While the long-term consequences of chemotherapy and surgery for head and neck cancer are relatively constrained, high-dose radiotherapy (RT) and chemoradiotherapy (CRT) substantially impact on local tissues and organ function and result in a significant rate of late mortality and morbidity in patients. Studies are now being designed to reduce the impact of RT and CRT for patients. Patients with intermediate stage HPV positive oropharyngeal cancer will be screened for poor prognostic features and undergo robotic surgery. Patients in whom pathology demonstrates good prognosis features will then be followed without postoperative radiotherapy. Patients with subsequent recurrence will be treated with either surgery and postoperative radiotherapy or postoperative chemoradiotherapy alone. Patients with poor prognostic features (ECS, LVI, PNI) will receive reduced dose radiotherapy or chemoradiotherapy based on pathology. It is expected that over 50% of patients treated with surgery will have had a curative treatment and will avoid radiation therapy entirely and long-term survival will not be changed by withholding radiation therapy to good prognosis patients after surgery. There are exploratory biomarkers of risk of recurrence that will be collected and studied. There are currently few trials examining the role of de-escalation using surgery alone in intermediate and early T-stage HPV related disease. New surgical techniques have broadened the range of patients capable of achieving a complete resection and the functional outcomes in such patients are outstanding. Furthermore, the sensitivity of HPVOPC to chemotherapy and radiotherapy raise the possibility that delayed or salvage treatment in early stage patients would be highly effective, wo
Conditions Studied
Interventions
- RADIATION Radiotherapy
- PROCEDURE PET/CT
- RADIATION Concurrent Chemoradiation
Study Locations (2)
New York
- Mount Sinai Beth Israel - New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2014-03 |
| Est. Completion | 2022-05-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02072148
The ClinicalTrials.gov registry entry for NCT02072148 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 620-participant average among 26 other Human Papilloma Virus trials with a reported enrollment target (82% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Papilloma Virus appearing as the primary indexed condition, and to 3 interventions - of which Radiotherapy is the first listed.
NCT02072148 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02072148 about?
NCT02072148 is a clinical study titled "The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)". In general, patients with Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma (HPVOPC) are curable, young and will live for prolonged periods. They are at high risk for long-term toxicity and mortality from therapy. While the long-term consequences of chemotherapy and surgery for he...
What is the current status of trial NCT02072148?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2014-03. Estimated completion is 2022-05-12.
What conditions does trial NCT02072148 study?
This clinical trial studies the following conditions: Human Papilloma Virus, Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT02072148?
The interventions under investigation include: Radiotherapy (RADIATION), PET/CT (PROCEDURE), Concurrent Chemoradiation (RADIATION).
Who is sponsoring clinical trial NCT02072148?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02072148 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
RECRUITING · NA
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
RECRUITING · NA
-
Impact of Standing Orders Optimization
ACTIVE NOT RECRUITING · NA
-
Development of a Self-collection Device for Cervical Cancer Screening
ACTIVE NOT RECRUITING · NA
-
Impact of Financial Incentives
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.